GeoVax Labs’ (GOVX) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a research report released on Thursday,Benzinga reports. They currently have a $18.00 price target on the stock.

Several other equities analysts have also commented on GOVX. Alliance Global Partners initiated coverage on GeoVax Labs in a research note on Monday, November 11th. They issued a “buy” rating and a $15.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of GeoVax Labs in a report on Friday, November 15th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $14.20.

GeoVax Labs Stock Down 2.7 %

Shares of NASDAQ:GOVX opened at $1.44 on Thursday. GeoVax Labs has a fifty-two week low of $1.09 and a fifty-two week high of $11.18. The firm’s 50-day simple moving average is $2.01 and its 200-day simple moving average is $2.65.

Institutional Trading of GeoVax Labs

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GOVX. Virtu Financial LLC bought a new position in GeoVax Labs during the 3rd quarter valued at about $97,000. Citadel Advisors LLC bought a new position in shares of GeoVax Labs during the 4th quarter valued at about $104,000. Northern Trust Corp acquired a new position in GeoVax Labs in the 4th quarter worth $29,000. Finally, Geode Capital Management LLC increased its stake in GeoVax Labs by 59.0% in the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after buying an additional 33,440 shares during the last quarter. Institutional investors and hedge funds own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.